Johnson & Johnson (JNJ): Price and Financial Metrics
Johnson & Johnson (JNJ)
Today's Latest Price: $147.06 USD
Updated Sep 29 4:00pm
Add JNJ to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 239 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
JNJ Stock Summary
- JNJ has a higher market value than 99.75% of US stocks; more precisely, its current market capitalization is $387,314,661,407.
- Johnson & Johnson's stock had its IPO on January 1, 1986, making it an older stock than 92.87% of US equities in our set.
- In terms of volatility of its share price, JNJ is more volatile than merely 0.44% of stocks we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to Johnson & Johnson are WMT, PG, TSM, MA, and TSLA.
- Visit JNJ's SEC page to see the company's official filings. To visit the company's web site, go to www.jnj.com.
JNJ Stock Price Chart Technical Analysis Charts
JNJ Price/Volume Stats
| Current price | $147.06 | 52-week high | $157.00 |
| Prev. close | $147.11 | 52-week low | $109.16 |
| Day low | $146.06 | Volume | 6,770,256 |
| Day high | $147.92 | Avg. volume | 8,385,094 |
| 50-day MA | $148.72 | Dividend yield | 2.75% |
| 200-day MA | $145.17 | Market Cap | 387.18B |
Johnson & Johnson (JNJ) Company Bio
Johnson & Johnson researches and develops, manufactures, and sells various products in the health-care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. Some of its well-known brands include Tylenol-fever, Listerine-bad breath, Splenda-no-calorie sweetener, Neutrogena-skin care, Pepcid-heartburn, Zyrtec - allergy, Motrin-ibuprofen, Sudafed-allergy, and plenty more. The company was founded in 1885 and is based in New Brunswick, New Jersey.
JNJ Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $147.06 | $64.04 | -56% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Johnson & Johnson. To summarize, we found that Johnson & Johnson ranked in the 26th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 56.17%. The most interesting components of our discounted cash flow analysis for Johnson & Johnson ended up being:
- The company has produced more trailing twelve month cash flow than 97.53% of its sector Healthcare.
- The business' balance sheet reveals debt to be 7% of the company's capital (with equity being the remaining amount). Approximately just 17.83% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
- JNJ's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 41.06% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -57% |
| 1% | -57% |
| 2% | -56% |
| 3% | -56% |
| 4% | -56% |
| 5% | -55% |
Want more companies with a valuation profile/forecast similar to that of Johnson & Johnson? See A, IONS, VIVO, HSIC, and RMD.
Loading social stream, please wait...